<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>608</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15483236</PubmedId>
            <Abstract>Human respiratory syncytial virus (RSV) is a major cause of respiratory infection in children and in the elderly. The RSV fusion (F) glycoprotein has long been recognized as a vaccine candidate as it elicits cytotoxic T-lymphocyte (CTL) and antibody responses. Two murine H-2K(d)-restricted CTL epitopes (F85-93 and F92-106) are known in the F protein of the A2 strain of RSV. F-specific CTL lines using BCH4 fibroblasts that are persistently infected with the Long strain of human RSV as stimulators were generated, and it was found that in this strain only the F85-93 epitope is conserved. Motif based epitope prediction programs and an F2 chain deleted F protein encoded in a recombinant vaccinia virus enabled identification of a new epitope in the Long strain, F249-258, which is presented by K(d) as a 9-mer (TYMLTNSEL) or a 10-mer (TYMLTNSELL) peptide. The results suggest that the 10-mer might be a naturally processed endogenous K(d) ligand. The CD8(+) T-lymphocyte responses to epitopes F85-93 and F249-258 present in the F protein of RSV Long were found to be strongly skewed to F85-93 in in vitro multispecific CTL lines and in vivo during a secondary response to a recombinant vaccinia virus that expresses the entire F protein. However, no hierarchy in CD8(+) T-lymphocyte responses to F85-93 and F249-258 epitopes was observed in vivo during a primary response.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>3229-3238</ArticlePages>
            <ArticleTitle>Shifting immunodominance pattern of two cytotoxic T-lymphocyte epitopes in the F glycoprotein of the Long strain of respiratory syncytial virus.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Johnstone</LastName>
                    <ForeName>Carolina</ForeName>
                </Author>
                <Author>
                    <LastName>de León</LastName>
                    <ForeName>Patricia</ForeName>
                </Author>
                <Author>
                    <LastName>Medina</LastName>
                    <ForeName>Francisco</ForeName>
                </Author>
                <Author>
                    <LastName>Melero</LastName>
                    <ForeName>José A</ForeName>
                </Author>
                <Author>
                    <LastName>García-Barreno</LastName>
                    <ForeName>Blanca</ForeName>
                </Author>
                <Author>
                    <LastName>Val</LastName>
                    <ForeName>Margarita Del</ForeName>
                </Author>
            </Authors>
            <Affiliations>Unidade de Inmunología Viral, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Ctra Pozuelo km 2, E-28220 Majadahonda (Madrid), Spain; Unidade de Biología Viral, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Ctra Pozuelo km 2, E-28220 Majadahonda (Madrid), Spain.</Affiliations>
            <ArticleChemicalList>Epitopes, T-Lymphocyte;Immunodominant Epitopes;Ligands;Respiratory Syncytial Virus Vaccines;Vaccines, Synthetic;Viral Proteins;Interferon-gamma</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Motifs(immunology); Animals; CD8-Positive T-Lymphocytes(immunology); Cell Count; Cells, Cultured; Epitopes, T-Lymphocyte(genetics; immunology); Humans; Immunodominant Epitopes; Interferon-gamma(analysis); Ligands; Mice; Respiratory Syncytial Virus Vaccines(biosynthesis; immunology); Respiratory Syncytial Virus, Human(immunology); Species Specificity; Spleen(immunology); T-Lymphocyte Subsets(immunology); T-Lymphocytes, Cytotoxic(immunology); Vaccines, Synthetic(biosynthesis; immunology); Vaccinia virus(genetics); Viral Proteins(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>85</Volume>
                <Issue>Pt 11</Issue>
                <Title>The Journal of general virology</Title>
                <Issn>0022-1317</Issn>
                <MedlineTa>J Gen Virol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>F85-93</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KYKNAVTEL</LinearSequence>
                        <StartingPosition>85</StartingPosition>
                        <EndingPosition>93</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03420.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11260</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Methods</LocationOfData>
                <EpitopeId>34485</EpitopeId>
                <ReferenceStartingPosition>85</ReferenceStartingPosition>
                <ReferenceEndingPosition>93</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Fusion glycoprotein precursor [Contains: Fusion glycoprotein F2;Fusion glycoprotein F1].</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 1C and 1D</LocationOfData>
                        <TCellId>5708</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>10E7 p.f.u. of vvF.  Booster given three weeks later p.i.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>CTL line generated from splenocytes was termed CTL F/RSV based on in vivo priming and in vitro restimulation.  Cells were restimulated weekly with IL-2 and RSV-infected spelenocytes.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>P815-Mast cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>169</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -Biological process measured</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>F85-93</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KYKNAVTEL</LinearSequence>
                                        <StartingPosition>85</StartingPosition>
                                        <EndingPosition>93</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03420.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11260</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Target cells derived from P815 mastocytoma cells (H-2-&lt;sup&gt;d&lt;/sup&gt;) pulsed with epitope were used to compare restimulated splenocytes with restimulated BCH4 fibroblasts. Both effectors gave similar results. The effector to target ratio varied from 1 to 200 with effective lysis seen above an E:T ratio of 10.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <TCellId>5717</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>10E7 p.f.u. of vvF.  Booster given three weeks later p.i.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>CTL line generated from splenocytes was termed CTL F/BCH4 based on in vivo priming and in vitro restimulation.  CTL F/BCH4 line was produced from splenocytes restimulated with BCH4 cells.  Cells were restimulated weekly with IL-2 and BCH4 cells.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>F85-93</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KYKNAVTEL</LinearSequence>
                                        <StartingPosition>85</StartingPosition>
                                        <EndingPosition>93</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03420.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11260</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>T2 cells transfected with murine K&lt;sup&gt;d&lt;/sup&gt; were used as target cells.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <TCellId>5719</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>10E7 p.f.u. of vvF δF2.  Booster given three weeks later p.i.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>CTL line generated from splenocytes was termed CTL δF2/BCH4 based on in vivo priming and in vitro restimulation.  CTL δF2 line was produced from mice infected with vv&amp;deltaF2 virus (which contains deletion of residues 34-128 of the F2 glycoprotein). Cells were restimulated weekly with IL-2 and BCH4 cells.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>F85-93</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KYKNAVTEL</LinearSequence>
                                        <StartingPosition>85</StartingPosition>
                                        <EndingPosition>93</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03420.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11260</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>T2 cells transfected with murine K&lt;sup&gt;d&lt;/sup&gt; were used as target cells.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>F249-258</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TYMLTNSELL</LinearSequence>
                        <StartingPosition>249</StartingPosition>
                        <EndingPosition>258</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03420.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11260</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Methods</LocationOfData>
                <EpitopeId>67390</EpitopeId>
                <ReferenceStartingPosition>249</ReferenceStartingPosition>
                <ReferenceEndingPosition>257</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Fusion glycoprotein precursor [Contains: Fusion glycoprotein F2;Fusion glycoprotein F1].</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 7</LocationOfData>
                        <TCellId>18026</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>10E7 p.f.u. of vvF δF2.  Booster given three weeks later p.i.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>CTL line generated from splenocytes was termed CTL &amp;deltaF2/BCH4 based on in vivo priming and in vitro restimulation.  CTL δF2/BCH4 line was produced from mice infected with vvδF2 (contains deletion of residues 34-128 of F2 glycoprotein).  Splenocytes were restimulated with weekly with IL-2 and BCH4 cells.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>F249-258</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TYMLTNSELL</LinearSequence>
                                        <StartingPosition>249</StartingPosition>
                                        <EndingPosition>258</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03420.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11260</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Comparison of CD8+ populations secreting IFN-γ in response to F249-257 and F249-258 peptides in CTL lines produced from infected BCH4 cells either encoding (CTL F/BCH4) or not encoding (CTL δF2/BCH4) the F2 region of the F protein (F2 contains F85-93 epitope) was performed.  A 5-10X increase in CD8+ cells recognizing F249-257/8 when the F2 region was deleted indicate subdominance of F249-257 and F249-258 eptiopes.  A comparison of the ability to stimulate the multispecific CTL δF2/BCH4 reveals that F249-258 (10mer) gives a much more robust response (98% v. 52%).</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3a (left panel)</LocationOfData>
                        <TCellId>18023</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>10E7 p.f.u. of vvF.  Booster given three weeks later p.i.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Multispecific CTL line generated from splenocytes was termed CTL F/BCH4 based on in vivo priming and in vitro restimulation.  CTL F/BCH4 line was produced by stimulation of primed mouse splenocytes with BCH4 fibroblasts persistently infected with RSV.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>F249-258</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TYMLTNSELL</LinearSequence>
                                        <StartingPosition>249</StartingPosition>
                                        <EndingPosition>258</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03420.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11260</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>This experiment compared the activation of multispecific CTL line CTL F/BCH4 by F249-257, F249-258, and F85-93 using a T2 assay.  F85-93 was most efficiently recognized, followed by F249-257 (9-mer) and then F249-258 (10-mer).</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>F249-257</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TYMLTNSEL</LinearSequence>
                        <StartingPosition>249</StartingPosition>
                        <EndingPosition>257</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03420.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11260</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Methods</LocationOfData>
                <EpitopeId>67389</EpitopeId>
                <ReferenceStartingPosition>249</ReferenceStartingPosition>
                <ReferenceEndingPosition>257</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Authors also experimented with a 10-mer containing the residues TYMLTNSELL with similar results. Fusion glycoprotein precursor [Contains: Fusion glycoprotein F2;Fusion glycoprotein F1].</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3A</LocationOfData>
                        <TCellId>18027</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>10E7 p.f.u. of vvF.  Booster given three weeks later p.i.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Multispecific CTL line generated from splenocytes was termed CTL F/BCH4 based on in vivo priming and in vitro restimulation.  CTL F/BCH4 line was produced by stimulation of primed mouse splenocytes with BCH4 fibroblasts persistently infected with RSV.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>F249-257</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TYMLTNSEL</LinearSequence>
                                        <StartingPosition>249</StartingPosition>
                                        <EndingPosition>257</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03420.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11260</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>This experiment compared the activation of multispecific CTL line CTL F/BCH4 by F249-257, F249-258, and F85-93 using a T2 assay.  F85-93 was most efficiently recognized, followed by F249-257 (9-mer) and then F249-258 (10-mer).</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 7</LocationOfData>
                        <TCellId>18030</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>10E7 p.f.u. of vvF δF2.  Booster given three weeks later p.i.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>CTL line generated from splenocytes was termed CTL &amp;deltaF2/BCH4 based on in vivo priming and in vitro restimulation.  CTL δF2/BCH4 line was produced from mice infected with vvδF2 (contains deletion of residues 34-128 of F2 glycoprotein).  Splenocytes were restimulated with weekly with IL-2 and BCH4 cells.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>F249-257</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TYMLTNSEL</LinearSequence>
                                        <StartingPosition>249</StartingPosition>
                                        <EndingPosition>257</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03420.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11260</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Comparison of CD8+ populations secreting IFN-γ in response to F249-257 and F249-258 peptides in CTL lines produced from infected BCH4 cells either encoding (CTL F/BCH4) or not encoding (CTL δF2/BCH4) the F2 region of the F protein (F2 contains F85-93 epitope) was performed.  A 5-10X increase in CD8+ cells recognizing F249-257/8 when the F2 region was deleted indicate subdominance of F249-257 and F249-258 eptiopes.  A comparison of the ability to stimulate the multispecific CTL δF2/BCH4 reveals that F249-258 (10mer) gives a much more robust response (98% v. 52%).</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <TCellId>18029</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>124</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>10E7 p.f.u. of vvF.  Booster given three weeks later p.i.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Multispecific CTL line generated from splenocytes was termed CTL F/BCH4 based on in vivo priming and in vitro restimulation.  CTL F/BCH4 line was produced from splenocytes restimulated with RSV-infected BCH4 cells.  Cells were restimulated weekly with IL-2 and BCH4 cells.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>F249-257</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TYMLTNSEL</LinearSequence>
                                        <StartingPosition>249</StartingPosition>
                                        <EndingPosition>257</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03420.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11260</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4A</LocationOfData>
                        <TCellId>18028</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P03420.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>F protein encoded in vaccinia virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>10245</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>10E7 p.f.u. of vvF.  Booster given three weeks later p.i.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>CTL line generated from splenocytes was termed CTL F/F249-257 based on in vivo priming and in vitro restimulation.  CTL F/F249-257 line was produced from splenocytes restimulated with F249-257.  Cells were restimulated weekly with IL-2 and RSV-infected splenocytes.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>F249-257</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TYMLTNSEL</LinearSequence>
                                        <StartingPosition>249</StartingPosition>
                                        <EndingPosition>257</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03420.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11260</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>T2 assay assessing activation of monospecific CTL line F/249-257 by the epitope was performed.  This was compared to the activation of the multispecific CTL line CTL F/BCH4 in a separate experiment.  Activation of monospecific CTL was better than CTL F/BCH4 suggesting F249-257 may be a subdominant epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>F31-40</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>EFYQSTCSAV</LinearSequence>
                        <StartingPosition>31</StartingPosition>
                        <EndingPosition>40</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03420.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11260</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Methods</LocationOfData>
                <EpitopeId>12113</EpitopeId>
                <ReferenceStartingPosition>31</ReferenceStartingPosition>
                <ReferenceEndingPosition>40</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Fusion glycoprotein precursor [Contains: Fusion glycoprotein F2;Fusion glycoprotein F1].</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 5 and article text</LocationOfData>
                        <TCellId>18031</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>10E7 p.f.u. of vvF δF2.  Booster given three weeks later p.i.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Multispecific CTL line generated from splenocytes was termed CTL F/BCH4 based on in vivo priming and in vitro restimulation.  CTL F/BCH4 line was produced by stimulation of primed mouse splenocytes with BCH4 fibroblasts persistently infected with RSV.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>169</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -Biological process measured</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>F31-40</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>EFYQSTCSAV</LinearSequence>
                                        <StartingPosition>31</StartingPosition>
                                        <EndingPosition>40</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03420.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11260</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Recognition of peptide-pulsed targets nor generation of monospecific CTL lines were observed with this predicted Kd-restricted epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>F32-40</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FYQSTCSAV</LinearSequence>
                        <StartingPosition>32</StartingPosition>
                        <EndingPosition>40</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03420.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11260</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Methods</LocationOfData>
                <EpitopeId>18454</EpitopeId>
                <ReferenceStartingPosition>32</ReferenceStartingPosition>
                <ReferenceEndingPosition>40</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Fusion glycoprotein precursor [Contains: Fusion glycoprotein F2;Fusion glycoprotein F1].</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 5 and text</LocationOfData>
                        <TCellId>18032</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>10E7 p.f.u. of vvF δF2.  Booster given three weeks later p.i.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Multispecific CTL line generated from splenocytes was termed CTL F/BCH4 based on in vivo priming and in vitro restimulation.  CTL F/BCH4 line was produced by stimulation of primed mouse splenocytes with BCH4 fibroblasts persistently infected with RSV.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>F32-40</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FYQSTCSAV</LinearSequence>
                                        <StartingPosition>32</StartingPosition>
                                        <EndingPosition>40</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03420.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11260</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Neither recognition of peptide-pulsed targets nor generation of monospecific CTL lines were observed with this predicted Kd-restricted epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>F92-106</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ELQLLMQSTPAANR</LinearSequence>
                        <SourceMolecule>
                            <IedbAccession>SRC280042</IedbAccession>
                        </SourceMolecule>
                        <SourceOrganismId>11260</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Methods</LocationOfData>
                <EpitopeId>13238</EpitopeId>
                <ReferenceStartingPosition>92</ReferenceStartingPosition>
                <ReferenceEndingPosition>106</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Internal Identifier-no external match available</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 5 and article text</LocationOfData>
                        <TCellId>18033</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>10E7 p.f.u. of vvF δF2.  Booster given three weeks later p.i.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Multispecific CTL line generated from splenocytes was termed CTL F/BCH4 based on in vivo priming and in vitro restimulation.  CTL F/BCH4 line was produced by stimulation of primed mouse splenocytes with BCH4 fibroblasts persistently infected with RSV.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>F92-106</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ELQLLMQSTPAANR</LinearSequence>
                                        <SourceMolecule>
                                            <IedbAccession>SRC280042</IedbAccession>
                                        </SourceMolecule>
                                        <SourceOrganismId>11260</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Neither recognition of peptide-pulsed targets nor generation of monospecific CTL lines were observed with this predicted Kd-restricted epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>F365-373</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>VFCDTMNSL</LinearSequence>
                        <StartingPosition>365</StartingPosition>
                        <EndingPosition>373</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03420.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11260</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Methods</LocationOfData>
                <EpitopeId>68436</EpitopeId>
                <ReferenceStartingPosition>365</ReferenceStartingPosition>
                <ReferenceEndingPosition>373</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Fusion glycoprotein precursor [Contains: Fusion glycoprotein F2;Fusion glycoprotein F1].</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 5 and article text</LocationOfData>
                        <TCellId>18034</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>10E7 p.f.u. of vvF δF2.  Booster given three weeks later p.i.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Multispecific CTL line generated from splenocytes was termed CTL F/BCH4 based on in vivo priming and in vitro restimulation.  CTL F/BCH4 line was produced by stimulation of primed mouse splenocytes with BCH4 fibroblasts persistently infected with RSV.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>F365-373</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VFCDTMNSL</LinearSequence>
                                        <StartingPosition>365</StartingPosition>
                                        <EndingPosition>373</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03420.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11260</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Neither recognition of peptide-pulsed targets nor generation of monospecific CTL lines were observed with this predicted Kd-restricted epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>F467-475</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LYVKGEPII</LinearSequence>
                        <StartingPosition>467</StartingPosition>
                        <EndingPosition>475</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03420.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11260</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Methods</LocationOfData>
                <EpitopeId>40984</EpitopeId>
                <ReferenceStartingPosition>467</ReferenceStartingPosition>
                <ReferenceEndingPosition>475</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Fusion glycoprotein precursor [Contains: Fusion glycoprotein F2;Fusion glycoprotein F1].</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 5 and article text</LocationOfData>
                        <TCellId>18035</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>10E7 p.f.u. of vvF δF2.  Booster given three weeks later p.i.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11260</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Multispecific CTL line generated from splenocytes was termed CTL F/BCH4 based on in vivo priming and in vitro restimulation.  CTL F/BCH4 line was produced by stimulation of primed mouse splenocytes with BCH4 fibroblasts persistently infected with RSV.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>F467-475</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LYVKGEPII</LinearSequence>
                                        <StartingPosition>467</StartingPosition>
                                        <EndingPosition>475</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03420.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11260</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Neither recognition of peptide-pulsed targets nor generation of monospecific CTL lines were observed with this predicted Kd-restricted epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

